Literature DB >> 22512636

Particle-mediated delivery of cytokines for immunotherapy.

David A Christian1, Christopher A Hunter.   

Abstract

The ability of cytokines to direct the immune response to vaccination, infection and tumors has motivated their use in therapy to augment or shape immunity. To avoid toxic side effects associated with systemic cytokine administration, several approaches have been developed using particle-encapsulated cytokines to deliver this cargo to specific cell types and tissues. Initial work used cytokine-loaded particles to deliver proinflammatory cytokines to phagocytes to enhance antimicrobial and antitumor responses. These particles have also been used to create a cytokine depot at a local site to supplement prophylactic or antitumor vaccines or injected directly into solid tumors to activate immune cells to eliminate established tumors. Finally, recent advances have revealed that paracrine delivery of cytokines directly to T cells has the potential to enhance T-cell mediated therapies. The studies reviewed here highlight the progress in the last 30 years that has established the potential of particle-mediated cytokine immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22512636      PMCID: PMC3395888          DOI: 10.2217/imt.12.26

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  148 in total

Review 1.  Protein instability in poly(lactic-co-glycolic acid) microparticles.

Authors:  M van de Weert; W E Hennink; W Jiskoot
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  Gamma interferon loaded onto albumin nanoparticles: in vitro and in vivo activities against Brucella abortus.

Authors:  S Segura; C Gamazo; J M Irache; S Espuelas
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

Review 3.  Liposomal vaccine delivery systems.

Authors:  Malou Henriksen-Lacey; Karen Smith Korsholm; Peter Andersen; Yvonne Perrie; Dennis Christensen
Journal:  Expert Opin Drug Deliv       Date:  2011-03-18       Impact factor: 6.648

4.  In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2.

Authors:  M E Neville; R J Robb; M C Popescu
Journal:  Cytokine       Date:  2001-12-21       Impact factor: 3.861

5.  Pharmacokinetics of an extended-release human interferon alpha-2b formulation.

Authors:  A Bonetti; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.

Authors:  J Hanes; A Sills; Z Zhao; K W Suh; B Tyler; F DiMeco; D J Brat; M A Choti; K W Leong; D M Pardoll; H Brem
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

7.  Immunoadjuvant activity of a liposomal IL-6 formulation.

Authors:  A J Duits; A van Puijenbroek; H Vermeulen; F M Hofhuis; J G van de Winkel; P J Capel
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

8.  Partial dissociation of antiviral and antimitogenic activities of murine interferon after its incorporation into liposomes.

Authors:  D A Eppstein; Y V Marsh
Journal:  J Interferon Res       Date:  1983

9.  Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.

Authors:  I J Fidler; A Raz; W E Fogler; R Kirsh; P Bugelski; G Poste
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

10.  Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.

Authors:  Bret D Ulery; Devender Kumar; Amanda E Ramer-Tait; Dennis W Metzger; Michael J Wannemuehler; Balaji Narasimhan
Journal:  PLoS One       Date:  2011-03-03       Impact factor: 3.240

View more
  24 in total

Review 1.  Exploiting homing abilities of cell carriers: Targeted delivery of nanoparticles for cancer therapy.

Authors:  Pamela Tiet; Jacob M Berlin
Journal:  Biochem Pharmacol       Date:  2017-09-21       Impact factor: 5.858

Review 2.  Nanomedicine approaches to improve cancer immunotherapy.

Authors:  Hui Qiu; Yuanzeng Min; Zach Rodgers; Longzhen Zhang; Andrew Z Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-03-10

Review 3.  Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.

Authors:  Vanessa Acebes-Fernández; Alicia Landeria-Viñuela; Pablo Juanes-Velasco; Angela-Patricia Hernández; Andrea Otazo-Perez; Raúl Manzano-Román; Rafael Gongora; Manuel Fuentes
Journal:  Nanomaterials (Basel)       Date:  2020-06-29       Impact factor: 5.076

Review 4.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

5.  Recombinant human granulocyte macrophage colony stimulating factor (hGM-CSF): Possibility of nanoparticle-mediated delivery in cancer immunotherapy.

Authors:  Selvarajan Vanitha; Nidhi Chaubey; Siddhartha S Ghosh; Pallab Sanpui
Journal:  Bioengineered       Date:  2016-07-26       Impact factor: 3.269

Review 6.  Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.

Authors:  Ronnie H Fang; Ashley V Kroll; Liangfang Zhang
Journal:  Small       Date:  2015-09-02       Impact factor: 13.281

Review 7.  Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets.

Authors:  Joe We Moss; Dipak P Ramji
Journal:  Future Med Chem       Date:  2016-06-30       Impact factor: 3.808

8.  Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.

Authors:  Brittany J Poelaert; Svetlana Romanova; Shelby M Knoche; Madeline T Olson; Bailee H Sliker; Kaitlin Smits; Brittney L Dickey; Alexandra E J Moffitt-Holida; Benjamin T Goetz; Nuzhat Khan; Lynette Smith; Hamid Band; Aaron M Mohs; Donald W Coulter; Tatiana K Bronich; Joyce C Solheim
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

Review 9.  Nanotechnology-based immunotherapies to combat cancer metastasis.

Authors:  Yuping Zhao; Muhammad Bilal; Maimoona Qindeel; Muhammad Imran Khan; Kuldeep Dhama; Hafiz M N Iqbal
Journal:  Mol Biol Rep       Date:  2021-08-23       Impact factor: 2.316

Review 10.  Biologics and their delivery systems: Trends in myocardial infarction.

Authors:  Matthew A Borrelli; Heth R Turnquist; Steven R Little
Journal:  Adv Drug Deliv Rev       Date:  2021-03-26       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.